GlassScriptPhysician profile
Catherine Clinton
NPI 1346268422
$5,095.54
in general payments reported to CMS, 2019-2025
35 companies · $680 in 2025
The $680 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $109 · 2021: $751 · 2022: $1,261 · 2023: $810 · 2024: $766 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,365.23 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Coopersurgical, INC. | $382.29 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $338.09 | 2022-2025 | Nexplanon, Jada System |
| Avion Pharmaceuticals | $296.30 | 2021-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $240.24 | 2022-2025 | |
| Pfizer INC. | $223.47 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $198.21 | 2019-2024 | Gardasil 9, Gardasil, Vaqta |
| Hologic Sales and Service, LLC | $192.52 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Agile Therapeutics, INC. | $183.93 | 2022-2023 | Twirla |
| Astellas Pharma US INC | $150.46 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $114.55 | 2024-2025 | Slynd |
| Biogen, INC. | $106.92 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $103.52 | 2019-2021 | |
| Myovant Sciences INC. | $99.74 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $85.16 | 2021 | |
| Allergan, INC. | $84.09 | 2019-2020 | |
| Novo Nordisk INC | $84.03 | 2023-2025 | Wegovy |
| Amag Pharmaceuticals, INC. | $74.53 | 2019 | |
| Dysis Medical, INC. | $70.97 | 2019-2022 | |
| Seqirus USA INC | $62.49 | 2024-2025 | Flucelvax, Fluad |
| Amgen INC. | $57.60 | 2024 | Prolia, Evenity |
| Channel Medsystems, INC. | $57.55 | 2022 | |
| Lupin INC. | $47.45 | 2019 | |
| Duchesnay USA Incorporated | $38.89 | 2019 | |
| Mission Pharmacal Company | $36.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.02 | 2019 | |
| Boston Scientific Corporation | $29.92 | 2019 | |
| Sumitomo Pharma America, INC. | $26.93 | 2023 | Myfembree |
| Exact Sciences Corporation | $21.90 | 2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $21.38 | 2021 | |
| Gynesonics, INC. | $19.81 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Monaghan Medical Corporation | $16.96 | 2023 | Aerochamber |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 | |
| Millicent US INC | $13.58 | 2025 | Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Clinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.